BIOXIS Pharmaceuticals

Bioxis Pharmaceuticals is developing MTI12, the world’s first Monophasic Tissular Inductor, using its proprietary chitosan technology that brings significant improvements to current dermal filler treatment. To bring MTI12 to market, the company has set up a fully integrated eco-system from research and development through raw materials manufacturing to production and distribution.

In addition to its MTI12 technology and in response to a huge demand for high quality crosslinked hyaluronic acid dermal fillers, Bioxis has developed CYTOSIAL, a complementary line of dermal fillers using its proprietary hyaluronic acid technology. Launched in April 2017.